VPH1 Antibody

What is VPH1 and why is it important in V-ATPase research?

VPH1 encodes a 95-kDa integral membrane polypeptide (Vph1p) that functions as one of two isoforms of the V₀ a-subunit in yeast V-ATPases. Vph1p is specifically localized to the vacuolar membrane and is essential for V-ATPase assembly and function. While not required for cell viability, VPH1 deletion results in complete loss of vacuolar acidification and disassembly of the V-ATPase complex, as the peripherally bound nucleotide-binding subunits (V₁ sector) no longer associate with the membrane-embedded V₀ sector in vph1 mutants .

Vph1p serves as both a structural component of the V-ATPase complex and plays a critical role in proton transport across the vacuolar membrane. Its importance is highlighted by the fact that vacuoles purified from yeast bearing vph1 mutations lack bafilomycin-sensitive ATPase activity and ATP-dependent proton pumping . Vph1p-containing V-ATPases are regulated by glucose availability through reversible disassembly, making them valuable for studying metabolic regulation of cellular processes.

How do different monoclonal antibodies recognize VPH1 protein?

Several monoclonal antibodies have been developed that recognize the Vph1 protein with varying specificity. Based on the research literature, there are at least two well-characterized monoclonal antibodies:

• 10D7 antibody: This monoclonal antibody specifically recognizes native Vph1 and chimeric constructs containing the C-terminal domain of Vph1, but does not cross-react with Stv1 (the other a-subunit isoform) or chimeras lacking the Vph1 C-terminus .

• 7B1H1 antibody: This monoclonal antibody shows broader reactivity, recognizing both Vph1 and certain chimeric constructs containing portions of Stv1 and Vph1 .

These differential recognition patterns make these antibodies particularly valuable for studying chimeric V-ATPase constructs and distinguishing between V-ATPase complexes with different a-subunit compositions. The specificity patterns suggest that these antibodies recognize different epitopes within the Vph1 protein, allowing researchers to probe specific domains of the protein.

What are the optimal protocols for using VPH1 antibodies in immunoprecipitation experiments?

Immunoprecipitation experiments using VPH1 antibodies require careful optimization to maintain V-ATPase complex integrity. Based on established protocols for V-ATPase studies, the following methodology is recommended:

• Sample preparation: For each immunoprecipitation, collect cell culture equivalent to approximately 20-50 OD₆₀₀ units and convert to spheroplasts using standard protocols .

• Glucose treatment: To study assembly/disassembly, incubate spheroplasts in media with (+) or without (-) 2% glucose at 30°C for 30 minutes. For reassembly studies, include a third sample (-/+) incubated without glucose for 20 minutes followed by 30 minutes with 2% glucose addition .

• Cell lysis: Lyse spheroplasts in cold extraction buffer (typically 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.1 mM EDTA) using glass beads, followed by centrifugation to remove cell debris .

• Pre-clearing: Add Sepharose A beads to pre-clear the suspension and remove by centrifugation .

• Antibody incubation: Add the appropriate amount of anti-Vph1 antibody (typically 5-10 μl) to the supernatant and rock at 4°C for 4-6 hours .

• Capture and washing: Add Protein A Sepharose beads, incubate for 2 hours at 4°C, then wash three times with cold extraction buffer .

• Elution: Elute immunoprecipitated proteins with hot cracking buffer (8M urea, 50mM Tris-HCl pH 6.8, 5% SDS, 1mM EDTA) at 55-95°C for 10-20 minutes .

• Analysis: Perform SDS-PAGE and Western blotting using appropriate antibodies against V₁ and V₀ subunits to assess V-ATPase assembly state .

This protocol can be modified depending on the specific antibody used and the experimental question being addressed.

How can VPH1 antibodies be used to study V-ATPase assembly state?

VPH1 antibodies are valuable tools for monitoring V-ATPase assembly state, particularly in response to glucose availability. The following methodological approach is recommended:

• Co-immunoprecipitation analysis: Use anti-Vph1 antibodies to immunoprecipitate V₀ complexes, then probe for co-precipitating V₁ subunits (A, B, C, etc.) to assess assembly state. Alternatively, immunoprecipitate with antibodies against V₁ subunits (such as 13D11 against B-subunit) and probe for co-precipitating Vph1 .

• Quantitative assessment: Calculate the ratio of V₀ to V₁ in immunoprecipitates from samples with different glucose treatments to quantify assembly state. Normalize to the ratio in glucose-replete conditions .

• Membrane fractionation approach: Isolate vacuolar vesicles and assess the relative amounts of V₁ subunits associated with the membrane by Western blotting. Compare the levels of V₁ subunits (A, B, C) to V₀ subunits (Vph1, subunit d) to determine assembly state .

• Activity correlation: Correlate assembly state with V-ATPase activity by measuring concanamycin A-sensitive ATPase activity and proton pumping in parallel samples .

This multi-faceted approach provides robust assessment of V-ATPase assembly state and can reveal the effects of mutations, stress conditions, or chemical treatments on the complex.

How can VPH1 antibodies be used to study the RAVE complex interaction with V-ATPases?

The RAVE (Regulator of H⁺-ATPase of Vacuoles and Endosomes) complex plays a crucial role in V-ATPase assembly, particularly for Vph1-containing V-ATPases. VPH1 antibodies can be used to study this interaction through several advanced approaches:

• Interaction domain mapping: VPH1 antibodies can help identify which domains of Vph1 interact with the RAVE complex. Research has shown that the cytosolic N-terminal domain of Vph1 (Vph1NT) binds directly to the Rav1 subunit of RAVE, specifically to a conserved six-amino acid motif in Rav1 (amino acids 824-829) .

• Glucose-dependent interactions: By comparing Vph1-RAVE co-immunoprecipitation under different glucose conditions, researchers can study how glucose regulates this interaction. This approach revealed that the RAVE-Vph1 interaction is glucose-dependent, but the conserved Rav1 motif required for Vph1 binding is not responsible for glucose sensitivity .

• In vitro binding assays: Recombinant Vph1NT and Rav1 fragments can be used in pull-down assays to assess direct binding. Specifically, His₆-tagged Rav1 fragments (such as Rav1 679-898) can be incubated with Vph1NT and TALON resin, followed by elution with imidazole and immunoblotting with anti-Vph1 antibodies .

• Mutational analysis: VPH1 antibodies can assess the effects of mutations in either Vph1 or RAVE components on their interaction. For example, the rav1 6Δ mutation prevents RAVE recruitment to the vacuolar membrane by disrupting Rav1-Vph1 binding .

A comprehensive experimental setup would combine these approaches to understand both the structural requirements and regulatory mechanisms of RAVE-Vph1 interactions.

How can VPH1 antibodies differentiate between native and chimeric V-ATPase a-subunits?

The differential reactivity of VPH1 antibodies with native and chimeric a-subunits makes them powerful tools for studying engineered V-ATPases. This application is particularly valuable when investigating how different domains contribute to V-ATPase localization, activity, and regulation.

Researchers have created chimeric a-subunits by swapping domains between Vph1 (vacuolar isoform) and Stv1 (Golgi/endosomal isoform). Two specific chimeras have been well-characterized:

• SPVD chimera: Contains the N-terminal cytosolic domain of Stv1 and the C-terminal membrane domain of Vph1 .

• VPSD chimera: Contains the N-terminal cytosolic domain of Vph1 and the C-terminal membrane domain of Stv1 .

The antibody recognition patterns for these chimeras are:

• 7B1H1 antibody: Recognizes Vph1 and the SPVD chimera

• 10D7 antibody: Recognizes only Vph1 and VPSD, but not SPVD

• Anti-Stv1 polyclonal: Recognizes VPSD and SPVD but not Vph1

This differential recognition allows researchers to:

• Confirm the expression and stability of chimeric constructs

• Track the localization of chimeric V-ATPases in cellular fractionation experiments

• Assess assembly state and regulation of chimeric V-ATPases compared to native complexes

When implementing this approach, researchers should include appropriate controls and be aware that epitope accessibility may be affected by protein conformation or complex assembly state.

What controls should be included when using VPH1 antibodies in biochemical assays?

When using VPH1 antibodies in biochemical assays, the following controls are essential to ensure reliable and interpretable results:

• Specificity controls:

  • Include samples from vph1Δ strains to confirm antibody specificity

  • Use stv1Δ strains as positive controls for Vph1-specific detection

  • For chimeric constructs, include both parent proteins (Vph1 and Stv1) as references

• Loading and normalization controls:

  • Include a stable vacuolar membrane protein such as alkaline phosphatase (ALP) for normalization in vacuolar purification experiments

  • Assess total protein levels in whole cell extracts to ensure equivalent starting material

• Functional controls:

  • Measure concanamycin A-sensitive ATPase activity to correlate protein detection with functional V-ATPases

  • Use proton pumping assays (such as 9-amino-6-chloro-2-methoxyacridine quenching) to verify V-ATPase functionality

• Assembly state controls:

  • Compare glucose-starved (-) and glucose-replete (+) samples to calibrate assembly/disassembly responses

  • Include reassembly (-/+) samples when studying assembly dynamics

• Antibody validation controls:

  • Test antibody dilution series to ensure operation in the linear range of detection

  • Include secondary antibody-only controls to assess non-specific binding

By implementing these controls, researchers can confidently interpret results and troubleshoot unexpected findings in VPH1 antibody-based experiments.

What are the technical challenges in using VPH1 antibodies for immunolocalization studies?

Immunolocalization of Vph1 using specific antibodies presents several technical challenges that researchers should be aware of:

• Epitope accessibility: The membrane-embedded nature of Vph1 means that certain epitopes may be poorly accessible in intact cells or even in membrane preparations. Consider using mild detergents or fixation methods that maintain protein conformation while improving accessibility.

• Cross-reactivity concerns: When studying both Vph1 and Stv1 simultaneously, antibody cross-reactivity must be carefully controlled. The 10D7 antibody shows high specificity for Vph1, making it preferable for distinguishing between the two isoforms .

• Fixation compatibility: Some antibodies perform poorly with certain fixation methods. Test different fixatives (formaldehyde, glutaraldehyde, methanol) to optimize signal while maintaining cellular architecture.

• Background reduction: Vacuolar membranes can exhibit high background fluorescence. Implementing blocking steps with BSA or non-fat milk, and including detergent (0.1% Triton X-100) in washing steps can improve signal-to-noise ratio.

• Validation approaches: Confirm specificity using vph1Δ strains as negative controls and complemented strains as positive controls. For super-resolution microscopy, consider dual-labeling with known vacuolar markers.

• Native versus epitope-tagged proteins: Consider whether using epitope-tagged Vph1 (with GFP, HA, or Myc tags) might provide better visualization than direct antibody detection, particularly if antibody performance is suboptimal.

By addressing these challenges methodically, researchers can successfully use VPH1 antibodies for high-quality immunolocalization studies of V-ATPases.

How should data from VPH1 antibody experiments be quantified and statistically analyzed?

• Western blot quantification:

  • Use software such as ImageJ to quantify band intensities

  • Always include loading controls for normalization (ALP for vacuolar membranes)

  • Calculate ratios of V₁:V₀ subunits to assess assembly state

  • Perform at least three biological replicates for statistical validity

• Immunoprecipitation analysis:

  • Quantify co-immunoprecipitated proteins relative to the immunoprecipitated protein

  • Calculate the percentage of total protein recovered in immunoprecipitates

  • For assembly studies, normalize data to glucose-replete conditions

• Statistical considerations:

  • Apply appropriate statistical tests based on experimental design (typically ANOVA with multiple comparisons for comparing different strains or conditions)

  • Report both mean and standard deviation across replicates

  • Consider non-parametric tests if data do not follow normal distribution

• Binding assays quantification:

  • For in vitro binding studies (such as PIP binding experiments), subtract non-specific binding (control without PIP) from total binding

  • Calculate PIP-specific binding by multiplying percentage of protein in pellet by total protein concentration

• Activity correlation analysis:

  • Correlate protein levels with functional measurements (ATPase activity, proton pumping)

  • Use concanamycin A-sensitive activity for V-ATPase-specific measurements

  • Express specific activity in μmol/min/mg protein

How can VPH1 antibodies help resolve conflicting models of V-ATPase regulation?

VPH1 antibodies serve as critical tools for resolving competing models of V-ATPase regulation, particularly regarding the mechanisms of glucose-dependent assembly/disassembly. Several approaches using these antibodies can address specific controversies:

• RAVE recruitment versus V₁ binding model:

  • One model suggests that glucose regulates RAVE recruitment to Vph1, while another proposes direct regulation of V₁-V₀ interaction

  • Using VPH1 antibodies in co-immunoprecipitation experiments with RAVE components showed that RAVE recruitment to the membrane does not require an interaction with V₁, supporting independent regulation

  • Quantitative analysis revealed that RAVE localization did not correlate with V-ATPase assembly levels, highlighting the catalytic nature of RAVE's role

• Signaling pathway identification:

  • VPH1 antibodies can track assembly state in mutants affecting various signaling pathways

  • Co-immunoprecipitation experiments in these mutants can determine whether glucose signaling to RAVE occurs independently of V₁

• Isoform-specific regulation:

  • Using the differential reactivity of antibodies against Vph1 and Stv1

  • Comparative analysis showed that only V-ATPases containing the Vph1 isoform require RAVE for their assembly, suggesting isoform-specific regulatory mechanisms

• In vitro reconstitution experiments:

  • Purified components can be combined with recombinant proteins to test direct interactions

  • This approach demonstrated that the conserved motif in Rav1 is directly involved in interaction with Vph1NT rather than indirectly affecting glucose sensing

By systematically applying VPH1 antibodies in these contexts, researchers have clarified that glucose-dependent RAVE localization to the vacuolar membrane required only intact V₀ complexes containing Vph1, supporting a model where the RAVE-V₀ interaction is the primary glucose-dependent step .

How can VPH1 antibodies be used to study engineered V-ATPases with altered regulatory properties?

VPH1 antibodies present powerful tools for characterizing engineered V-ATPases with modified regulatory properties. Recent research demonstrates this application through the analysis of chimeric a-subunit constructs:

• Characterization of functional chimeras:

  • The SPVD chimera (containing the N-terminal domain of Stv1 and C-terminal domain of Vph1) creates functional V-ATPases with altered regulatory properties

  • VPH1 antibodies such as 7B1H1 can confirm expression and proper assembly of these engineered complexes

• Activity-structure correlations:

  • V-ATPase activity measurements combined with immunoblotting using VPH1 antibodies can reveal how structural modifications affect function

  • This approach showed that SPVD chimeras maintain full activity, while VPSD chimeras have significantly reduced assembly and activity

• Regulatory property assessment:

  • Immunoprecipitation under different glucose conditions can evaluate whether engineered V-ATPases maintain normal glucose-dependent regulation

  • This approach revealed the first example of a "redesigned" V-ATPase with altered regulatory properties and adaptation to specific stresses

• Domain function analysis:

  • Differential antibody reactivity can help map functional domains within Vph1

  • By correlating antibody recognition with function in chimeric constructs, researchers can identify critical regions for assembly, activity, and regulation

• Future applications:

  • Design of synthetic V-ATPases with novel regulatory properties

  • Creation of V-ATPases responsive to new environmental signals

  • Development of V-ATPases with enhanced stability or activity for biotechnological applications

This emerging field demonstrates how VPH1 antibodies facilitate not only understanding of native V-ATPase biology but also the creation and characterization of engineered proton pumps with novel properties.

What methodological advances are improving VPH1 antibody applications in research?

Recent methodological advances have expanded the utility of VPH1 antibodies in V-ATPase research:

• Improved protein purification techniques:

  • Tandem affinity purification (TAP) tags combined with VPH1 antibodies allow isolation of intact V-ATPase complexes

  • Recombinant expression systems for Vph1 domains enable detailed interaction studies

  • The use of TALON resin with His₆-tagged proteins provides cleaner background for pull-down assays

• Advanced microscopy applications:

  • Super-resolution microscopy with VPH1 antibodies enables visualization of V-ATPase distribution at unprecedented detail

  • Single-molecule tracking approaches can follow individual V-ATPase complexes in living cells

  • Correlative light and electron microscopy can connect V-ATPase localization with ultrastructural features

• Quantitative binding assays:

  • Development of more sensitive techniques for measuring protein-protein and protein-lipid interactions

  • PIP-binding assays with quantitative analysis using ImageJ provide precise measurements of domain-specific interactions

• Functional coupling analyses:

  • Combined electrophysiology and immunodetection approaches link structure to function

  • Real-time proton pumping assays correlated with complex assembly state

  • Coupling of ATPase activity measurements with assembly state assessment using concanamycin A sensitivity

• Cryo-EM structural analysis:

  • Antibody-based purification provides samples for high-resolution structural studies

  • Epitope mapping using VPH1 antibodies can validate structural predictions

  • Integration of functional data with structural information

These methodological advances continue to expand the research applications of VPH1 antibodies, enabling increasingly sophisticated analyses of V-ATPase structure, function, and regulation.